Media Articles Related to Relistor (Methylnaltrexone Subcutaneous)
FDA OKs Plecanatide for Chronic Idiopathic Constipation
Source: Medscape Family Medicine Headlines [2017.01.19]
The new once-daily oral medication was proven to improve the frequency of spontaneous bowel movements.
Synergy Wins FDA Approval for Constipation Drug
Source: MedPage Today Gastroenterology [2017.01.19]
(MedPage Today) -- Trulance approved for chronic idiopathic constipation in adults
Health Tip: Concerned About Constipation?
Source: MedicineNet Constipation Specialty [2017.01.12]
Title: Health Tip: Concerned About Constipation?
Category: Health News
Created: 1/12/2017 12:00:00 AM
Last Editorial Review: 1/12/2017 12:00:00 AM
Source: MedicineNet Anal Fissure Specialty [2016.11.10]
Title: Laxatives (Constipation)
Category: Diseases and Conditions
Created: 9/24/1999 12:00:00 AM
Last Editorial Review: 11/10/2016 12:00:00 AM
Can Castor Oil Be Used For Treating Constipation?
Source: Irritable Bowel Syndrome News From Medical News Today [2016.10.18]
Constipation can conspire to ruin your day. What causes constipation and how can we prevent it? Learn how castor oil and other treatments may help
Published Studies Related to Relistor (Methylnaltrexone Subcutaneous)
Subcutaneous methylnaltrexone for treatment of acute opioid-induced constipation:
phase 2 study in rehabilitation after orthopedic surgery. 
patients with acute OIC after orthopedic procedures... CONCLUSIONS: Methylnaltrexone was generally well tolerated and was active in
Safety and efficacy of methylnaltrexone in shortening the duration of postoperative ileus following segmental colectomy: results of two randomized, placebo-controlled phase 3 trials. [2011.05]
PURPOSE: Postoperative ileus contributes to surgical morbidity and is associated with prolonged hospitalization and increased health care costs. The efficacy and safety of the peripherally acting mu-opioid receptor antagonist methylnaltrexone in shortening the duration of postoperative ileus following segmental colectomy was evaluated... CONCLUSIONS: Although the efficacy of methylnaltrexone in reducing the duration of postoperative ileus was not demonstrated in these studies, intravenous methylnaltrexone at doses of 12 mg and 24 mg was safe, in general, and well tolerated in postcolectomy patients. The utility of intravenous methylnaltrexone in treating postoperative ileus remains unproven.
Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. [2011.05]
Methylnaltrexone is effective for opioid-induced constipation (OIC) in advanced illness patients. This 4-week, double-blind, randomized, placebo-controlled study investigated the effect of subcutaneous methylnaltrexone on OIC in patients receiving opioids for chronic, nonmalignant pain...
Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms. [2011.01]
BACKGROUND: Methylnaltrexone, a selective peripheral acting mu-opioid receptor antagonist, alleviates the constipating effects of opioids without affecting centrally mediated analgesia. OBJECTIVES: To assess the effect of subcutaneous (SC) methylnaltrexone injection on patient-reported constipation symptoms and pain scores... CONCLUSION: The results of our study indicate significant improvement in constipation symptoms with methylnaltrexone QD or QOD dosing compared to placebo without a significant effect on pain scores. Copyright (c) 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.
Characterization of abdominal pain during methylnaltrexone treatment of
opioid-induced constipation in advanced illness: a post hoc analysis of two
clinical trials. 
studies... CONCLUSION: Abdominal pain AEs in methylnaltrexone-treated patients in clinical
Clinical Trials Related to Relistor (Methylnaltrexone Subcutaneous)
Methylnaltrexone for Opioid-induced Constipation in Cancer Patients [Completed]
Methylnaltrexone Pharmacokinetics in Neurointensive Care Patients [Recruiting]
- Assessment of pharmacokinetic parameters of once daily subcutaneously administered
methylnaltrexone in 10 evaluable neurointensive care patients.
- Quantification of methylnaltrexone passage through the blood-brain-barrier in
critically ill patients with severe cerebral affections.
- Observation of laxation response after methylnaltrexone application and relation to
plasma concentrations of methylnaltrexone.
- Assessing the safety of once daily administered methylnaltrexone in neurointensive care
- Trial with medicinal product
Effect of Methylnaltrexone on GI Transit in Healthy Volunteers [Completed]
This is a single-center, randomized, double blind, placebo-controlled study evaluating the
effects of placebo, codeine, methylnaltrexone and codeine with methylnaltrexone on
gastrointestinal motility and colonic transit of solids in healthy human subjects.
The hypotheses are:
1. Methylnaltrexone administered subcutaneously enhances gastrointestinal motility with
acceleration of overall colonic transit, and ascending colon emptying of solids in
2. Methylnaltrexone significantly accelerates colonic transit that is delayed by codeine
Methylnaltrexone for Treatment of Opiate-Induced Constipation in the Intensive Care Unit [Recruiting]
The purpose of this study is to determine if there will be a significantly higher incidence
of a bowel movement with methylnaltrexone vs. placebo within 4 hours +- 45 minutes with
decreased need for rescue medications in the intensive care unit in patients with
opioid-induced constipation. Patients will also be managed with an aggressive bowel
Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine [Not yet recruiting]
Ticagrelor is associated with more prompt and potent antiplatelet effects compared with
clopidogrel, leading to better clinical outcomes, including reduced cardiovascular
mortality, across the spectrum of patients with acute coronary syndrome, including those
with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary
intervention (PCI). However, in this latter setting a delay in the onset of its antiplatelet
effects has been shown. Morphine has been identified as a cause of delayed P2Y12 inhibition
in patients with STEMI. Methylnaltrexone is a parenteral peripheral opioid receptor
antagonist which has the potential to prevent or reverse opioid-induced peripherally
mediated side effects without affecting analgesia. However, whether the use of intravenous
methylnaltrexone may overcome the effects of morphine administration on the pharmacokinetic
(PK) and pharmacodynamics (PD) profiles of ticagrelor has not been investigated yet. The
proposed investigation will include patients with coronary artery disease and will have a
prospective, randomized, cross-over design.
Reports of Suspected Relistor (Methylnaltrexone Subcutaneous) Side Effects
Mental Status Changes (2),
Metabolic Acidosis (2),
NO Therapeutic Response (2),
Confusional State (1),
Haematocrit Decreased (1),
Abdominal Distension (1), more >>